Physician profile
Melissa King
NPI 1760421416
$15,073.33
in general payments reported to CMS, 2019-2025
36 companies · $2,008 in 2025
The $2,008 reported for 2025 was more than what 76% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,069 · 2020: $1,117 · 2021: $2,116 · 2022: $1,858 · 2023: $2,622 · 2024: $2,283 · 2025: $2,008.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,818 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,818.20 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,150.25 | 2019-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $1,687.86 | 2019-2020 | |
| Janssen Biotech, INC. | $1,355.19 | 2019-2025 | Tremfya |
| Ucb, INC. | $1,106.29 | 2019-2025 | Bimzelx, Cimzia |
| Amgen INC. | $1,007.58 | 2020-2025 | Otezla, Enbrel, Otezla |
| Genzyme Corporation | $795.71 | 2021-2025 | |
| Pfizer INC. | $726.63 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $716.23 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $691.37 | 2019-2025 | Absorica Ld, Winlevi, Ilumya |
| Leo Pharma INC. | $622.19 | 2019-2025 | Adbry |
| Regeneron Healthcare Solutions, INC. | $589.48 | 2019-2025 | Dupixent |
| Incyte Corporation | $587.65 | 2022-2025 | Opzelura |
| Lilly USA, LLC | $529.14 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Arcutis Biotherapeutics, INC. | $525.26 | 2023-2025 | Zoryve |
| Dermavant Sciences, INC. | $363.72 | 2022-2024 | Vtama |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $348.66 | 2019-2025 | Nemluvio |
| Vyne Pharmaceuticals INC. | $242.42 | 2020-2021 | |
| Almirall LLC | $130.03 | 2019-2021 | |
| Allergan, INC. | $128.45 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $105.32 | 2024-2025 | Sotyktu |
| Mayne Pharma Commercial LLC | $101.00 | 2019 | |
| Mallinckrodt Hospital Products INC. | $100.58 | 2021 | |
| Celgene Corporation | $63.28 | 2019 | |
| Epi Health, LLC | $61.63 | 2019-2021 | |
| Ani Pharmaceuticals, INC. | $51.75 | 2025 | Purified Cortrophin Gel |
| Organon LLC | $44.59 | 2025 | Vtama |
| Verrica Pharmaceuticals INC. | $42.84 | 2023 | Ycanth |
| Prugen, INC. Pharmaceuticals | $37.75 | 2019 | |
| Aclaris Therapeutics, INC. | $31.35 | 2019 | |
| Journey Medical Corporation | $28.74 | 2022 | |
| Kyowa Kirin, INC. | $25.67 | 2022 | |
| Genentech USA, INC. | $17.74 | 2019 | |
| Medtronic Vascular, INC. | $15.36 | 2020 | |
| Helsinn Therapeutics (U.S.), INC. | $15.27 | 2019 | |
| Medtronic, INC. | $14.03 | 2021 | |
| Sebela Pharmaceuticals INC. | $12.32 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa King listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.